Skip to content

Multicenter study on the clinical features of the new stage 0 in patients with chronic obstructive pulmonary disease

Multicenter study on the clinical features of the new stage 0 in patients with chronic obstructive pulmonary disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16009181
Enrollment
Unknown
Registered
2016-09-10
Start date
2016-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

1:no

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged between 40 and 65 years. Gender and race are not limited; 2. Meeting the following 1 standard: (1) Smoking is more than 10 pack/ years; (2) Have a history of contacting with smoke or dust; (3) After reversible test, the FEV1/FVC is between 0.70 and 0.75; (4) Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Any other respiratory diseases are diagnosed:asthma, interstitial pneumonia, pulmonary tuberculosis, community-acquired pneumonia, bronchiectasis, lung cancer, pulmonary embolism, etc; other system diseases: coronary heart disease, myocarditis, heart failure, neuromuscular disease, decompensated liver cirrhosis, etc.; 2. Blood ALT or AST exceeded the upper limit of 2 times the normal value and blood Cr exceeded the upper limit of 1.5 times the normal value; 3. Left ventricular dysfunction, or nausea; 4. Positive HIV; 5. Acute cerebrovascular event (stroke, transient ischemic attack, acute coronary syndrome) in past 3 months; 6. Pregnant or planning a pregnancy or pregnancy; 7. Underwent pneumonectomy surgery or other lung function may affect the test results of all the operation in the past 12 months; 8. Not a cure for cancer; 9. Drinking, drug addiction, with a history of mental illness, no cooperation with the relevant examination of the project due to mental problems or other reasons; 10. In other drug clinical trials, or less than 3 months of the cessation time; 11. Not suitable for follow-up subjects; 12. Not signing the informed consent form; 13. Researchers believe that other reasons are not suitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
The incidence of COPD;The clinical manifestations in the COPD GOLD 0;The drop speed of pulmonary function in COPD GOLD 0;Risk factors of COPD GOLD 0;

Countries

China

Contacts

Public ContactLiang Dong

Qilu Hospital of Shandong University

dl5506@126.com+86 0531 8269331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026